gilead sciences

Subscribe to Breaking News Alerts

Remdesivir Priced At More Than $3,100 For A Course Of Treatment

Gilead Sciences, maker of the antiviral drug remdesivir, has come up with a price for the COVID-19 treatment that was less than some analysts expected. ULRICH PERREY/POOL/AFP via Getty Images hide caption

toggle caption

ULRICH PERREY/POOL/AFP via Getty Images

Shots - Health News

Remdesivir Priced At More Than $3,100 For A Course Of Treatment

June 29, 2020 • An experimental COVID-19 medicine that has been shown to shorten the time people with severe illness have to stay in the hospital finally has a price tag that's lower than some analysts expected.

Remdesivir Priced At More Than $3,100 For A Course Of Treatment

Listen · 4:12 4:12

Transcript

Download
Embed <iframe src="https://www.npr.org/player/embed/884648842/884958712" width="100%" height="290" frameborder="0" scrolling="no" title="NPR embedded audio player">
Transcript

Gilead Lobbying Rose As Interest In COVID-19 Treatment Climbed

Gilead Sciences CEO Daniel O'Day speaks at a meeting with President Trump and members of the White House coronavirus task force on March 2. Andrew Harnik/AP hide caption

toggle caption

Andrew Harnik/AP

Shots - Health News

Gilead Lobbying Rose As Interest In COVID-19 Treatment Climbed

May 2, 2020 • On Friday, the Food and Drug Administration authorized emergency use of remdesivir for patients with severe cases of COVID-19. Drugmaker Gilead Sciences' lobbying hit a new high in the first quarter.

Gilead Declines 'Rare Disease' Status For Experimental Coronavirus Drug

After the Food and Drug Administration granted Gilead Sciences orphan drug status for its experimental drug remdesivir on Tuesday, Gilead asked that the agency rescind that status Wednesday. Bloomberg/Bloomberg via Getty Images hide caption

toggle caption

Bloomberg/Bloomberg via Getty Images

Shots - Health News

Gilead Declines 'Rare Disease' Status For Experimental Coronavirus Drug

March 25, 2020 • By renouncing the special status, Gilead Sciences lets go of tax breaks, fee waivers and seven years without generic competition for remdesivir, its experimental COVID-19 treatment.